|
A Phase III Trial of Continuous Schedule AC + G vs q.2wk schedule AC, followed by Paclitaxel given either every 2wks or weekly for 12wks as post-op adjuvant therapy in node + or high-risk node negative breast cancer (SO221):
- Stage I, II, or III node positive or high-risk node negative breast cancer with known ER/PR status
- High risk tumor that is greater than 2cm
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer (NSABP B-37):
- Pathologically confirmed first local and/or regional recurrence of invasive breast cancer following primary treatment with mastectomy or breast conserving treatment
- No evidence of distant metastasis
Program for the Assessment of Clinical Cancer Tests; Trial Assigning Individualized Options for Treatment: The TAILORx Trial. (ECOG PACCT-1):
- Newly diagnosed with early-stage (I or II) breast cancer
- Tumor is estrogen and/or progesterone receptor positive, is HER2 receptor negative, and measures 1.1 to 5 cm
- Uses a modern diagnostic test (Oncotype DX) that gives a Recurrence Score that indicates chance of Breast Cancer recurrence
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-up
Assessment. (S0500)
- Patients must be women with histologically confirmed breast cancer and clinical evidence of Stage IV disease.
- Patients must have measurable disease or bone only disease.
- Patients must not have received any prior chemotherapy for metastatic disease.
|
